<DOC>
	<DOC>NCT01854229</DOC>
	<brief_summary>The Prometra Pump is approved by the FDA for use in the United States. The purpose of this study is to collect long-term safety data on the Prometra Pump.</brief_summary>
	<brief_title>Prometra Post-Approval Study</brief_title>
	<detailed_description>This study is proposed under part of the post-Premarket Approval (PMA) requirements. This study is a prospective, non-randomized, open-label, multicenter study. It will be performed at 10-30 centers in the US and enroll a maximum of 400 subjects. Subjects will be followed for a total of five years.</detailed_description>
	<mesh_term>Back Pain</mesh_term>
	<mesh_term>Chronic Pain</mesh_term>
	<mesh_term>Pain, Intractable</mesh_term>
	<criteria>1. Patient meets at least one of the following: is suffering from malignant pain (i.e., cancer pain) has chronic, nonmalignant pain subject was enrolled in PUMP I or PUMP II study and chooses to participate in this PostApproval study Patient with an existing implantable pump for pain therapy that requires replacement 2. Patient is at least 22 years of age. 3. Investigator considers the patient to be able and willing to fulfill all study requirements. 4. Patient has provided written informed consent to participate in the study. 1. Patient meets any of the contraindications for use of the Prometra System 2. Patient has a prior history of granuloma formation, or is receiving treatment for a suspected granuloma. 3. Patient is pregnant or breastfeeding or is of childbearing potential and not employing effective birth control.</criteria>
	<gender>All</gender>
	<minimum_age>22 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Morphine</keyword>
	<keyword>Implantable Infusion Pumps</keyword>
	<keyword>Intrathecal Pump</keyword>
</DOC>